^
    1d
    Cinderella-Neo: A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients. (clinicaltrials.gov)
    P2, N=42, Not yet recruiting, Fudan University
    New P2 trial
    |
    Perjeta (pertuzumab)
    1d
    Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial. (PubMed, Signal Transduct Target Ther)
    In conclusion, this randomized clinical trial met its primary outcome. Culmerciclib plus fulvestrant is well tolerated and leads to a significant gain in PFS of pretreated HR-positive HER2-negative ABC patients.
    Clinical • P3 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    fulvestrant • Setanxin (culmerciclib)
    1d
    Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort. (PubMed, Eur J Cancer)
    ET+CDK4/6i use rose up to ∼50 % after 2017, reaching ∼70 % in recent years among women with good PS, but remained ∼50 % in older patients with poor PS. Broader adoption is needed, with less chemotherapy use. Survival outcomes have improved but, causality cannot be confirmed due to the observational design.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    1d
    An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=86, Recruiting, BeOne Medicines | Not yet recruiting --> Recruiting
    Enrollment open
    2d
    PreEMBER: A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer (clinicaltrials.gov)
    P2, N=600, Not yet recruiting, Eli Lilly and Company
    New P2 trial
    |
    tamoxifen • Inluriyo (imlunestrant) • goserelin acetate
    2d
    Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=92, Recruiting, Aminex Therapeutics, Inc.
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • fulvestrant • Truqap (capivasertib) • AMXT 1501
    2d
    Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy (clinicaltrials.gov)
    P2, N=46, Recruiting, University of Nebraska | Trial completion date: Sep 2031 --> Sep 2032 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Ibrance (palbociclib)
    2d
    Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=205, Not yet recruiting, Novartis Pharmaceuticals
    New P1/2 trial
    |
    fulvestrant • letrozole
    3d
    FOURLIGHT-1: A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment (clinicaltrials.gov)
    P2, N=333, Active, not recruiting, Pfizer | Trial primary completion date: Sep 2025 --> Mar 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    everolimus • fulvestrant • exemestane • atirmociclib (PF-07220060)
    3d
    MCC-21622: Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies (clinicaltrials.gov)
    P1, N=3, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion
    |
    cyclophosphamide • fludarabine IV • PRGN-3007
    4d
    A Case of Grade 4 Hyperglycemia Induced by Capivasertib and Successfully Managed with Early Insulin Intervention. (PubMed, Surg Case Rep)
    Inpatient glucose monitoring enabled prompt detection of rapid glucose elevation and early intervention before the onset of DKA, resulting in a favorable outcome. Further clinical evidence is required to define optimal intervention strategies for grade 4 hyperglycemia associated with capivasertib therapy.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • EGFR positive
    |
    fulvestrant • Truqap (capivasertib)